

For release to Journalist and the Financial and Business sector

BioSpec Global Solutions Inc., announces new R&D project for testing pharmaceutical grade water used in line testing.

New York, Montreal , September 16, 2009 BioSpec Global Solutions Inc., and partner –**ICBS Ltd. (OTCPK: [ICBT](#))**, announced today a new R&D project development of a method for pharmaceutical process water in line testing.

Developing methods for TOGS 9000 to analyze total bacterial count in water samples. Application in pharmaceutical process water (in-line production testing). The development include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of Pharmaceutical water used in processing and manufacturing .

“Moving forward with this new R&D projects will allow the company to develop a wide range of testing procedures for the Pharmaceutical industry.” Said Don Saunders President and CEO BioSpec Global Solutions. “Without constant and proper testing there is always a health concern as water, whether it be drinking water or pharmaceutical grade water can become contaminated.

Having the ability to test water efficiently and quickly can provide pharmaceutical companies with the ability to monitor their production systems.

The Pro3000™ has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.

The company holds worldwide patents on the TOGS 3000 and 9000.

SOURCE: BioSpec Global Solutions Inc. www.biospecglobal.com

CONTACT: Don Saunders, President & CEO

TELEPHONE: 514-932-4402

www.icbs.ca

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.